Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis
disease diseaseOn this page
Also known as juvenile idiopathic rheumatoid factor-positive polyarthritispolyarthritis with rheumatoid factorpolyarticular JIA, RF+polyarticular juvenile idiopathic arthritis, RF+polyarticular juvenile idiopathic arthritis, rheumatoid Factor Positiverheumatoid factor-positive polyarticular JIA
Summary
Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis (MONDO:0019435) is a disease. A subtype of polyarticular juvenile idiopathic arthritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Europe)
- Phenotypes (HPO): 19
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | 4.2 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
19 HPO clinical features (Orphanet curated; top 19 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001369 | Arthritis | Very frequent (80-99%) |
| HP:0002829 | Arthralgia | Very frequent (80-99%) |
| HP:0002923 | Rheumatoid factor positive | Very frequent (80-99%) |
| HP:0005764 | Polyarticular arthritis | Very frequent (80-99%) |
| HP:0011117 | Abnormal circulating interleukin concentration | Frequent (30-79%) |
| HP:0001376 | Limitation of joint mobility | Frequent (30-79%) |
| HP:0001386 | Joint swelling | Frequent (30-79%) |
| HP:0002813 | Abnormality of limb bone morphology | Frequent (30-79%) |
| HP:0003565 | Elevated erythrocyte sedimentation rate | Frequent (30-79%) |
| HP:0005187 | Progressive joint destruction | Frequent (30-79%) |
| HP:0005930 | Abnormality of epiphysis morphology | Frequent (30-79%) |
| HP:0006252 | Interphalangeal joint erosions | Frequent (30-79%) |
| HP:0011227 | Elevated circulating C-reactive protein concentration | Frequent (30-79%) |
| HP:0040311 | Symetrical distal arthritis | Frequent (30-79%) |
| HP:0100769 | Synovitis | Frequent (30-79%) |
| HP:0000938 | Osteopenia | Occasional (5-29%) |
| HP:0004349 | Reduced bone mineral density | Occasional (5-29%) |
| HP:0010588 | Premature epimetaphyseal fusion | Occasional (5-29%) |
| HP:0100555 | Asymmetric growth | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | rheumatoid factor-positive polyarticular juvenile idiopathic arthritis |
| Mondo ID | MONDO:0019435 |
| EFO | EFO:0009731 |
| Orphanet | 85435 |
| NCIT | C119034 |
| UMLS | C3890733 |
| MedGen | 855737 |
| GARD | 0019064 |
| Is cancer (heuristic) | no |
Also known as: juvenile idiopathic rheumatoid factor-positive polyarthritis · polyarthritis with rheumatoid factor · polyarticular JIA, RF+ · polyarticular juvenile idiopathic arthritis, RF+ · polyarticular juvenile idiopathic arthritis, rheumatoid Factor Positive · rheumatoid factor-positive polyarticular JIA
Disease family
This is a subtype of polyarticular juvenile idiopathic arthritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › connective tissue disorder › rheumatic disorder › juvenile idiopathic arthritis › polyarticular juvenile idiopathic arthritis › rheumatoid factor-positive polyarticular juvenile idiopathic arthritis
Related subtypes (1): rheumatoid factor-negative juvenile idiopathic arthritis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.